Serum marker predicts cardiovascular events in diabetes

Serum marker predicts cardiovascular events in diabetes

(HealthDay)—Elevated levels of polyclonal serum immunoglobulin combined free light chains (cFLCs) may indicate adverse cardiovascular disease (CVD) outcomes in patients with type 2 diabetes, according to research published online April 17 in Diabetes Care.

Srikanth Bellary, M.B.B.S., of Aston University in Birmingham, U.K., and colleagues conducted a of 352 South Asian patients with type 2 diabetes to assess the association between cFLCs and cardiovascular disease events.

The researchers found that, among patients with type 2 diabetes who had CVD events during two years of follow-up, cFLC levels were elevated in 8 percent (50.7 versus 42.8 mg/L; P = 0.004). According to , elevated cFLC level (greater than 57.2 mg/L) was associated with adverse CVD outcomes (odds ratio, 3.3; 95 percent confidence interval, 1.3 to 8.2; P = 0.012). This association remained significant after adjustment for age, albumin-to-creatinine ratio, diabetes duration, or treatment.

"cFLC elevation is a novel marker for CVD outcomes in type 2 diabetes that warrants further investigation," the authors write.

The United Kingdom Asian Diabetes Study and several study authors received funding from pharmaceutical companies.


Explore further

Health behavior change cuts CVD risk after T2DM diagnosis

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Diabetes Care

Copyright © 2014 HealthDay. All rights reserved.

Citation: Serum marker predicts cardiovascular events in diabetes (2014, April 25) retrieved 22 November 2019 from https://medicalxpress.com/news/2014-04-serum-marker-cardiovascular-events-diabetes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments